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Unique proteome signature of 
post-chemotherapy ovarian cancer 
ascites-derived tumor cells
Nuzhat Ahmed1,2,3,4,*, David Greening5,*, Chantel Samardzija3, Ruth M. Escalona3,4, 
Maoshan Chen5, Jock K. Findlay3,4 & George Kannourakis1,2
Eighty % of ovarian cancer patients diagnosed at an advanced-stage have complete remission after 
initial surgery and chemotherapy. However, most patients die within <5 years due to episodes 
of recurrences resulting from the growth of residual chemoresistant cells. In an effort to identify 
mechanisms associated with chemoresistance and recurrence, we compared the expression of proteins 
in ascites-derived tumor cells isolated from advanced-stage ovarian cancer patients obtained at 
diagnosis (chemonaive, CN) and after chemotherapy treatments (chemoresistant/at recurrence, CR) 
by using in-depth, high-resolution label-free quantitative proteomic profiling. A total of 2,999 proteins 
were identified. Using a stringent selection criterion to define only significantly differentially expressed 
proteins, we report identification of 353 proteins. There were significant differences in proteins 
encoding for immune surveillance, DNA repair mechanisms, cytoskeleton rearrangement, cell-cell 
adhesion, cell cycle pathways, cellular transport, and proteins involved with glycine/proline/arginine 
synthesis in tumor cells isolated from CR relative to CN patients. Pathway analyses revealed enrichment 
of metabolic pathways, DNA repair mechanisms and energy metabolism pathways in CR tumor cells. 
In conclusion, this is the first proteomics study to comprehensively analyze ascites-derived tumor cells 
from CN and CR ovarian cancer patients.
Ovarian cancer is usually not detected until late in the advanced-stages (stage III–IV), when it has spread beyond 
ovaries to the adjacent abdominal organs1. Initially, most (~80%) advanced-stage patients respond to surgical 
debulking and chemotherapy treatment, but almost all relapse within a few months due to drug-resistant resid-
ual disease2. The five year survival period of advanced-stage ovarian cancer patients has remained unchanged 
and disappointingly low at ~30% for the last thirty years3. Hence, there is an urgent need to understand the 
mechanisms of recurrence and chemoresistance in order to design future treatment strategies which will provide 
long-term disease-free and overall survival periods for ovarian cancer patients.
The progression of ovarian cancer is characterized by rapid growth and spread of peritoneal tumors, and in 
most cases is accompanied by accumulation of ascites within the peritoneum1, which either in the chemonaive 
or chemoresistant phase carries a bad prognosis3,4. Malignant ascites constitutes a dynamic reservoir of survival 
factors, including cytokines, chemokines, growth factors, and extracellular matrix (ECM) fragments which indi-
vidually and in a combined fashion affect tumor cell growth and progression through different cellular mecha-
nisms4. Ascites also contains a complex mixture of ‘resident cells’ such as tumor and cancer associated fibroblasts 
or stromal cells and ‘non-resident cells’ such as infiltrating immune cells and bone-marrow derived mesenchymal 
stem cells4. Each population of cells has a defined role and is connected with each other through signaling by the 
‘in house’ soluble factors4. Tumor cells within the ascites of ovarian cancer patients are present either as single 
cells or more commonly as aggregates of non-adherent cells commonly known as spheroids5,6. In this scenario, 
multiple (a few hundred) tumor aggregates can be seen either floating or embedded in the peritoneal cavity dur-
ing primary debulking surgery1,5. Hence, there is a considerable heterogeneity in the ascites tumor population of 
ovarian cancer patients.
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In the past several years, studies have reported proteomic analyses of ascites fluid in an attempt to identify 
biomarkers for ovarian cancer7–9. However, to date no study has been done on ascites-derived tumor cells isolated 
from chemonaive and chemoresistant patients to understand the mechanisms of chemoresistance and associated 
recurrence. A limited number of studies have identified differentially expressed proteins between parental and 
in vitro drug-induced chemoresistant cell lines10–12 which have showed some relevance to the potential mecha-
nisms of chemoresistance in clinical samples. However, isolated tumor cells in the ascites of cancer patients that 
have survived chemotherapy treatments and re-emerged as recurrent tumors are likely to experience in vivo pro-
teome changes that would allow them to withstand the cytotoxic pressure of chemotherapy. We hypothesize that 
these ‘therapy resistant distinct’ tumor cells are likely to display a proteomic signature associated with chemore-
sistance which is different from that of the proteome of isolated tumor cells of chemonaive patients.
In the present study we have used our recently described novel separation technique to isolate tumor cells 
from the ascites of advanced-stage chemonaive and recurrent serous ovarian cancer patients5. Ascites were 
collected from patients at the time of surgery prior to chemotherapy treatment (CN) and at recurrence (CR). 
In this preliminary study, label-free quantitative proteomics was used to identify and monitor protein expres-
sion changes associated with chemoresistance and recurrence, utilising a set of unmatched CN (n = 4) and CR 
(n = 4) patient-derived samples. The overall aim was to identify a ‘unique proteome signature’ distinct to the 
ascites-derived tumor cells of CR patients so that novel information about specific proteins and pathways asso-
ciated with the chemoresistant/recurrent trait of tumor cells in the ascites can be obtained. Our data identified 
novel and differentially expressed proteins and associated pathways which will provide better understanding of 
the intraperitoneal spread of recurrent ovarian cancer. To our knowledge, this is the first study using comparative 
proteomic analysis to describe the unique protein signature between ascites-derived tumor cells from CN and 
CR patients.
Methods and Materials
Patient Recruitment. Ascites were collected from patients diagnosed with advanced-stage serous ovar-
ian carcinoma after obtaining written informed consent under protocols approved by the Research and Human 
Ethics Committee (HEC # 09/09) of The Royal Women’s Hospital, Melbourne, Australia. The histopathological 
diagnosis, tumor grades and stages were determined by independent staff pathologists as part of the clinical diag-
nosis. All patients recruited were diagnosed with high grade serous carcinomas (Supplementary Table S1). Ascites 
(As) samples (500 ml-2 L) were obtained before surgery from patients with primary carcinoma (n = 4), and at the 
time of recurrence following chemotherapy treatment (n = 4). Ascites collected prior to treatment were termed 
chemonaive (CN), while those collected from patients diagnosed with recurrent disease within 6–20 months after 
their original diagnosis and which has been treated with chemotherapy were termed chemoresistant/recurrent 
(CR). The chemotherapy agents and number of chemotherapy cycles administered to patients varied from patient 
to patient and are indicated in Supplementary Table S1.
Harvest of tumor cells from ascites of ovarian cancer patients. Tumor cells from fresh ascites 
samples were isolated as described previously5. Following isolation, ascites tumor cells (usually 105–106 cells) 
were cultured on low attachment plates (Corning Incorporated, NY) in MCDB: DMEM growth medium (50:50) 
supplemented with heat inactivated fetal bovine serum (10%), glutamine (2 mM) and penicillin/streptomycin 
(2 mM) (Life Technologies, CA, USA). Cells were maintained at 37 °C in the presence of 5% CO2 and tumor cells 
floating as non-adherent spheroid populations were collected after 2–3 days. Non-adherent cells were screened 
for CA125, EpCAM, cytokeratin 7 (CK7) and fibroblast surface protein (FSP) by Flow Cytometry to assess their 
purity before being stored at − 80°C until required for analysis.
Primary cell lysate preparation. Tumor cells were washed (ice cold PBS) and lysed on ice with SDS sam-
ple buffer (4% (w/v) SDS, 20% (v/v) glycerol, 0.01% (v/v) bromophenol blue, 0.125 M Tris-HCl, pH 6.8). Lysates 
were subjected to ultracentrifugation for 30 min at 4 °C (386,000 × g, TLA-100 rotor, Beckman Coulter), and 
soluble supernatants aspirated for downstream use, or frozen at − 80 °C.
Proteomic analysis. Protein content was estimated by 1D-SDS-PAGE/SYPRO® Ruby protein staining-based 
densitometry, as previously described13. Proteomic experiments were performed on primary cell lysates (n = 4) in 
technical duplicate as described previously14. Briefly, lysates from CN or CR tumor cells (10 μ g) were separated by 
short-range SDS-PAGE (10 mm), and visualized by Imperial Protein Stain (Invitrogen, Thermo Fisher Scientific, 
Australia). Individual samples (n = 2, equal gel slices of 7 × 5 mm) were excised, destained (50 mM ammonium 
bicarbonate/acetonitrile), reduced [10 mM DTT (Calbiochem, Merck, Australia) for 30 min], alkylated [50 mM 
iodoacetic acid for 30 min] and trypsinized [0.2 μ g trypsin (Promega Sequencing Grade, Australia) for 16 h at 
37 °C]. A nanoflow UPLC instrument (Ultimate 3000 RSLCnano, Thermo Fisher Scientific) was coupled on-line 
to an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Australia) with a nanoelectrospray ion source 
(Thermo Fisher Scientific). Peptides were loaded (Acclaim PepMap100, 5 mm × 300 μ m i.d., μ -Precolumn 
packed with 5 μ m C18 beads, Thermo Fisher Scientific, Australia) and separated (Acquity UPLC M-Class Peptide 
BEH130, C18, 1.7 μ m, 75 μ m × 250 mm, Waters, Australia). Data was acquired using Xcalibur software v2.1 
(Thermo Fisher Scientific). Details of the operation of the mass spectrometer are described previously14.
Database searching and protein identification. Raw data was processed using Proteome Discoverer 
(v1.4.0.288) and searched with Mascot (Matrix Science, London, UK; v 1.4.0.288), Sequest (Thermo Fisher 
Scientific, San Jose, CA, v 1.4.0.288), and X! Tandem (v 2010,12.01.1) against a database of 125,803 ORFs (Uniprot 
Human, Jul-2015) and common contaminants. Data was searched as described previously15,16 with a parent tol-
erance of 10 ppm, fragment tolerance of 0.5 Da and minimum peptide length 7, with FDR 1% at the peptide and 
protein levels. Scaffold (Proteome Software Inc., Portland, OR, v 4.3.4) was employed to validate MS/MS-based 
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peptide and protein identifications from database searching. Data was further examined using semi-quantitative 
label-free spectral counting13,16,17. Ratio of spectral count [Rsc (CR/CN)] values were normalised by the total 
number of significant MS/MS spectra identified in each sample and fold change ratios calculated. Total number 
of spectra was only counted for significant peptides identified (Ion score ≥ Homology score). When Rsc was less 
than 1, the negative inverse value was used. The number of significant assigned spectra for each protein was used 
to determine protein expression differences. For each protein the Fisher’s exact test was applied to significant 
assigned spectra. The resulting p-values were corrected for multiple testing using the Benjamini-Hochberg proce-
dure and statistics performed as previously described18. Contaminants and reverse database identifications were 
excluded from data analysis.
Protein identifications were accepted, if they reached greater than 99% probability and contained at least 
2 identified unique peptides. These identification criteria typically established < 1% false discovery rate based 
on a decoy database search strategy at the protein level. Proteins that contained similar peptides and could 
not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. 
Contaminants, and reverse identification were excluded from further data analysis. UniProt was used for pro-
tein annotation (molecular function/subcellular localisation) and KEGG (http://www.genome.jp/kegg/pathway.
html) and DAVID (http://david.abcc.ncifcrf.gov/) for pathway enrichment analyses. Corrplot (R package, https://
cran.r-project.org/web/packages/corrplot/) and Cluster (v3.0)19 were used to evaluate the correlation across all 
the samples and combined samples. MEGA (v6.06)20 was used to visualize the phylogeny tree. Raw data set of 
proteins identified in CN and CR tumor cells is described in Supplementary Table 2.
SDS-PAGE and Western blot analysis. SDS-PAGE and Western blot was performed on tumor cell 
lysates by the methods described previously21. For immunoblotting, cell lysates (n = 4) (10 μ g) resolved on 
10% SDS-PAGE and transferred to nitrocellulose membranes were probed with primary antibodies [mouse 
anti-human (1:1000)], TOP2A (Cell Signaling Technology, Danvers, MA, USA), PYCR2 and PPL (Santa Cruz 
Biotechnology, Dallas, USA) for 1 h in TTBS [50 mM Tris, 150 mM NaCl, 0.05% (v/v) Tween 20] followed 
by incubation with corresponding secondary antibodies; IRDye 800 goat anti-mouse IgG or IRDye 700 goat 
anti-rabbit IgG (1:15000, LI-COR Biosciences), for 1 h at room temperature in TTBS. Immunoblots were imaged 
using the CLx Odyssey Infrared Imaging System, (v3.0, LI-COR Biosciences, Nebraska USA). Loading con-
trols were obtained by staining the membrane with Deep Purple Total Protein stain as previously described15,16. 
Semi-quantitative densitometric analysis was performed on all blots (3 biological replicates) to determine the 
level of protein expression using ImageStudio v5, with mean pixel intensity of the protein of interest normalised 
to the background.
Statistical analysis. Student’s t-test was used for statistical analysis which involved comparison between two 
groups. Unless otherwise stated, data are presented as mean ± SEM (n = 4 biological replicates), with * p < 0.05 
considered statistically significant. Data was analysed using the GraphPad Prism Software v5. All experiments 
were repeated three times unless otherwise indicated.
Results
Isolation and characterisation of ascites-derived tumor cells. Ascites-derived tumor cells from both 
CN (n = 4) and CR patients (n = 4) were assessed by phase contrast microscopy after seeding on low attachment 
plates for 24 h (Fig. 1A). As previously described6, two distinct populations of cells were observed; (i) non-adher-
ent cellular aggregates (spheroids) that floated as three-dimensional structures in the growth medium without 
attachment to the plates (Fig. 1A), and (ii) spindle shaped fibroblast-like single cells that adhered to the low 
attachment plates5. Based on our previous studies which identified non-adherent population to be tumorigenic5, 
only non-adherent spheroid populations were assessed by Flow Cytometry in this study (Fig. 1A). As described 
previously5, high expression of cancer antigen 125 (CA125) and cytokeratin 7 (CK7) was observed in the cells 
dispersed from non-adherent spheroids, while no significant expression of fibroblast surface protein (FSP) was 
evident.
Proteome analysis of ascites-derived tumor cells before and after chemotherapy treatments. 
To identify possible mechanisms responsible for chemoresistance and associated recurrence in serous ovarian 
cancer patients, we compared the expression of proteins in non-adherent tumor cells isolated from the ascites of 
untreated (CN) and chemotherapy treated (CR) serous ovarian cancer patients. Using high-resolution mass spec-
trometry analysis, the ascites-derived CN and CR tumor cell populations showed a high degree of similarity in 
relation to protein content portraying an average of 2807 and 2775 proteins (Fig. 1B–D, Supplementary Table S2). 
There was a high degree of correlation between the samples of the same cohort, with the 4 CN samples showing 
correlation of 52.7% while 47.6% correlation was noted between the 4 CR samples (Fig. 1B). A correlation plot 
between the samples is presented in Fig. 1C, while Fig. 1D represents a relationship tree portraying significant 
differences between CN and CR samples.
For the purpose of analyzing the significant differences between CN and CR samples, a selection criteria was 
applied and only proteins which were differentially expressed at p < 0.05, and which exhibited a fold change 
of > 2 were only included in the study. In addition, proteins identified as ‘cDNA-like proteins’ were excluded 
from the analysis. An outline of the protein selection criteria is described in (Fig. 2A). On this basis, a com-
bined total of 353 proteins were identified to be differentially expressed between CN and CR samples (Fig. 2B,C) 
(Supplementary Table S3). Of these, 175 proteins were enriched in CR compared to CN samples, and 178 were 
diminished in CR compared to CN ascites-derived tumor cells. Of the 175 enriched proteins in CR compared to 
CN samples, 40% of the proteins were expressed in all 4 CR samples (number of peptides for each protein ranged 
between 222–5), 32% of the proteins in 3 CR samples (number of peptides for each protein ranged between 
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41–4), 20% in 2 CR samples (number of peptides for each protein ranged between 19–4) and 8% in 1 CR sample 
(number of peptides for each protein ranged between 20–4). On the other hand, among the 178 diminished 
proteins in CR samples compared to CN samples 12% of the proteins were expressed in 4 CR samples (number 
of peptides for each protein ranged between 246–4), 18% in 3 CR samples (number of peptides for each protein 
ranged between 48–3), 12% in 2 CR samples (number of peptides for each protein ranged between 22–2) and 25% 
in 1 CR sample (number of peptides for each protein ranged between 26–1). The remaining 37% of proteins were 
unique to CN samples and were not expressed in CR samples.
The top 10 proteins unique to CN samples (Fig. 2B, Supplementary Table S4) were MHC class 1 antigen 
(HLA-B) [Rsc = − 54.6], EVPL protein [Rsc = − 38.1], MHC class 1 antigen fragment (HLA-C) [Rsc = − 30.9], 
interferon induced GTP binding protein (MX2) [Rsc = − 20.9], Hematopoietic Cell kinase (HCK) [Rsc = − 14.5], 
Erlin-1(ERLIN1) [Rsc = − 14.5], spectrin alpha chain (SPTA1) [Rsc = − 12.3], protein AHNAK2 [Rsc = − 11.6], 
Lymphocyte antigen 75 (Ly-75) [Rsc = − 10.9] and unconventional myosin Vb (MYO5B) [Rsc = − 10.9] (Table 1), 
Other CN unique proteins of interest commonly expressed in carcinomas were Indolamine 2,3 dioxygenase 
(IDO1) [Rsc = − 10.2], Protein arginine deiminase (PADI2) [Rsc = − 8.8], Prostaglandin G/H synthase 2 (PTGS2/ 
COX-2) [Rsc = − 8.8], Kynureninase [Rsc = − 8.2] and Urokinase-type plasminogen activator chain B (PLAU) 
[Rsc = − 6.6], Mucin-4 beta chain (MUC4) [Rsc = − 5.9] (Supplementary Table S4).
The top ten proteins unique to CR tumor cells (Fig. 2B, Supplementary Table S5) were glycine decarboxylase 
(GLDC) [Rsc = 19.9], glutathione S-transferase Mu 3 (GST-M3) [Rsc = 19.9], MHC class II antigen (HLA-DRB1) 
[Rsc = 15.5] , acetyl-CoA carboxylase 1 (ACACA) [Rsc = 12.8], Histidyl-tRNA synthetase (HRS) [Rsc = 11.9], 
Rab3 GTPase-activating protein catalytic subunit (RAB3GAP1) [Rsc = 11.0], cyclin-dependent kinase inhibi-
tor 2 A (CDKN2A) [Rsc = 9.2], DNA mismatch repair protein (MSH6) [Rsc = 9.2], condensin complex subunit 
1 (NACAPD2) {Rsc = 9.2], ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1) [Rsc = 8.3] (Table 2). 
Other CR unique proteins which commonly are reported to be associated with the progression and chemore-
sistance of ovarian carcinomas were Aurora kinase A and B (AURKA and AURKB) [Rsc = 5.6], metastasis asso-
ciated protein-1 (MTA-1) [Rsc = 5.6], etc. In addition, C-reactive protein (CRP) [Rsc = 4.7] which is commonly 
elevated in the serum of ovarian cancer patients was also unique to CR tumor population and was not expressed 
in CN ascites-derived tumor cells (Supplementary Table S5).
Figure 1. Morphological features of ascites-derived spheroids. (A) Representative light microscopy images 
of non-adherent spheroid tumor populations grown on low-attachment plates derived from CN and CR serous 
ovarian cancer patient ascites samples. Images are representative of n = 4 samples/group. Arrows indicate non-
adherent spheroid ascites tumour populations. Magnification is set at 100x, scale bar = 100μ M. (B) CN and 
CR non-adherent spheroid cellular samples were profiled using discovery-based proteomics. Samples were 
analyzed as technical replicates (n = 2), stringent peptide and protein identification criteria were implemented 
(1% FDR protein, 5% PEP), with proteins requiring at least two significant peptides for identification. For 
CN samples (2807 proteins identified, 1482 proteins in common across CN1-4), while for CR samples (2775 
proteins identified, 1320 proteins in common across CR1–4). (C) Correlation matrix of CN (1–4 replicates and 
combined) and CR (1–4 replicates and combined) samples showing that each individual sample represents high 
similarity with other sample replicates of the same cohort. (D) Cluster analysis of CN and CR replicates showing 
clear distribution between sample groups.
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Of the proteins identified, 244 were seen to be commonly expressed in both CN and CR ascites-derived tumor 
populations (Fig. 2B, Supplementary Table S6). One hundred and twenty nine common proteins were seen to 
be enriched in CR samples compared to CN samples, while 115 proteins were identified to be diminished in CR 
versus CN samples. Of the top 10 common proteins identified to be most enriched in CR samples included col-
lagen alpha-1(XII) (COL12A) [Rsc = 12.1] which topped the list (Table 3). This was followed by Asparagine syn-
thetase (ASNS) [Rsc = 10.6], Squalene synthase (FDFT1) [Rsc = 6.6], UDP-glucose 6-dehydrogenase (UGDH) 
[Rsc = 6.4], Pyrroline-5-carboxylate reductase 2 (PYCR2) [Rsc = 5.8], Cleavage and polyadenylation specific fac-
tor subunit 3 (CPSF3) [Rsc = 5.6], Phosphoserine aminotransferase, FAD synthase (FLAD1) [Rsc = 5.3], laminin 
subunit alpha-5 (LAMA5) [Rsc = 5.1], Methyl transferase-like protein 7B (METTL7B) [Rsc = 5.1]. Other pro-
teins significantly enriched in CR included DNA Topoisomerase 2-alpha (TOP2A) [Rsc = 3.7], Agrin (AGRN) 
[Rsc = 3.1], Propionyl CoA carboxylase (PCCB), Protein DJ-1 {Rsc = 3.0]{Cao, 2015 #78}, Perilipin [Rsc = 3.0], 
Elongation factor 1-alpha 1 (EEF1A1), Macrophage migration inhibitory factor (MIF) [Rsc = 2.5], Signal trans-
ducer and activation of transcription (STAT3)[Rsc = 2.2], Transferrin (TF) [Rsc = 2.0], Proliferating cell nuclear 
antigen (PCNA) [Rsc = 2.0], A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAM-TS 
1) [Rsc = 2.1], Multidrug resistance associated protein 4 (ATP binding cassette sub family C member 4) 
Figure 2. Work flow of proteomic profiling of ascites-derived CN and CR tumor cells and summary of 
differentially expressed proteins. (A) Workflow for the proteomic profiling ovarian cancer ascites-derived 
tumor cells. Biological replicates of CN (n = 4) and CR (n = 4) patient ascites-derived tumor cell lysates were 
separated by 1D-SDS-PAGE (10 μ g). Individual gel slices were excised and subjected to in-gel reduction, 
alkylation, and tryptic digestion. Extracted peptides were separated by reverse phase–high performance liquid 
chromatography (RP-HPLC), followed by mass spectrometry analysis (technical duplicates), database searching 
and protein annotation. Normalized differential protein expression (Rsc, ratio of spectral counts) ranked as 
maximal difference between CR and CN samples. Proteins which met the selection criteria of p < 0.05 (Fisher’s 
exact test) and Rsc > ± 2 are listed and included for further analysis. (B) A two-way Venn diagram summarizing 
the number of proteins in CN and CR cell lysates which meet the selection criteria (p < 0.05, Rsc ± 2), with 
contaminants and proteins identified as ‘cDNA-like’ excluded from analysis. In total, 353 proteins were found 
to meet the selection criteria. Two-hundred and forty-four proteins were found to be commonly identified in 
both CN and CR samples. Of these, 129 proteins were enriched in CR samples compared to CN, while 115 were 
diminished in CR compared to CN samples. In all, 178 proteins were found to be diminished in CR samples 
(enriched in CN) and 175 proteins were enriched in CR samples. (C) Differential expression (Rsc) ranked as 
maximal difference between CR and CN. Proteins induced/repressed in expression are displayed (Rsc ± 2), 
while proteins with p-values < 0.05 are shown (* ).
www.nature.com/scientificreports/
6Scientific RepoRts | 6:30061 | DOI: 10.1038/srep30061
(ABCC4) and others (Supplementary Table S6). In addition, several proteins which previously have been shown 
to be elevated in the serum of ovarian cancer patients such as Chitinase-3-like protein 1(CHI3L1) [Rsc = 4.5], 
Haptoglobin (HP) [Rsc = 4.0] and Alpha-2-macroglobulin (A2M) [Rsc = 2.5] were elevated in CR.
The common protein most diminished in CR compared to CN samples was Dehydrogenase/reductase SDR family 
member 9 (DHRS9) [Rsc = − 13.0] (Table 4, Supplementary Table S6). This was followed by Prostacyclin synthase 
(PTGIS) [Rsc = − 8.1], endothelin-converting enzyme 1(ECE1) [Rsc = − 6.7], Periplakin (PPL) [Rsc = − 6.4], 
high mobility group protein B2 (HMG-B2) [Rsc = − 5.7], interferon induced protein (IFIT2) [Rsc = − 5.7], 
laminin subunit gamma-2 (LAMC2) [Rsc = 5.3], hepatoma derived growth factor (HDGF) [Rsc = − 5.1], carni-
tine O-acetyltransferase (CRAT) [rsc = − 4.9] and melanotransferrin (melanoma associated antigen p97, CD228, 
MFI2) [Rsc = − 4.9]. Other common diminished proteins of interest in CR were Placental Alkaline phosphatase 
(ALPP) [Rsc = − 4.3], Calcium and integrin binding protein − 1 (CIB-1) [Rsc = − 4.2], Plectin (PLEC) [Rsc = − 4.1], 
Ankyrin 1(ANK1) [Rsc = − 4.2], Annexin-9 (ANXA9) [Rsc = − 3.9], Transaldolase (TAlDO1) [Rsc = − 3.7], integrin 
beta 8 (ITGB8) [Rsc = − 3.3], Collagen alpha 1 (COL6A1) [Rsc = − 3.0], and Epiplakin (EPPK1) [Rsc = − 3.0] 
and others (Supplementary Table S6).
Validation of candidate proteins by Western blot. To confirm expression of selected proteins from 
proteomic profiling between the CN and CR populations, validation of a subset of proteins was carried out using 
immunoblotting (Fig. 3A,B). The proteins selected have been shown previously to be expressed in high-grade 
ovarian tumors and/or to have a role in drug-resistance. For Western blot analysis we examined the expression 
(in three independent experiments) of TOP2A, PYCR2 and PPL on the CN and CR samples used for proteomic 
analysis. Based on these results, the expression of TOP2A was significantly greater in CR than CN tumor cells 
(approx 1.5 fold) (Fig. 3A,B). This elevated expression was consistent with the proteomic profiling analysis, in 
which the Rsc (CR/CN) value of TOP2A was 3.7 fold higher in CR compared to CN tumor cells (Supplementary 
Tables S2 and S6). Although proteomic profiling analysis identified a significant enrichment of PYCR2 in CR 
samples compared to CN samples, the increase in protein expression was not deemed significant by Western blot 
(1.2 fold change). This may be due to weak signal of the PYCR2 antibody used against the target protein (PYCR2) 
in Western blot analysis which did not exactly correlate with the more sensitive mass spectrometry-based pro-
teomic profiling. PPL which was found to be diminished in CR (Rsc = − 6.4), (Supplementary Tables S2 and 6) by 
proteomic profiling and showed a similar pattern by Western blot (− 2.2- fold change) (Fig. 3A,B).
Protein 
Accession
Gene 
symbol Protein Description CN CR RSC Gene ontology (GO)
Q860I7 HLA-B MHC class I antigen 75 0 − 54.5
MHC class I protein complex; antigen processing and 
presentation of peptide antigen via MHC class I; immune 
response; integral component of membrane; peptide antigen 
binding; positive regulation of T cell mediated cytotoxicity
B7ZLH8 EVPL EVPL protein 52 0 − 38.1 cytoskeleton
I6NXG5 HLA-C MHC class I antigen 42 0 − 30.9
MHC class I protein complex; antigen processing and 
presentation of peptide antigen via MHC class I; immune 
response; peptide antigen binding; positive regulation of T 
cell mediated cytotoxicity
P20592 MX2 Interferon-induced GTP-binding protein Mx2 28 0 − 20.9
GTP binding; GTPase activity; cytosol; defense response 
to virus; mRNA transport; nuclear pore; protein transport; 
regulation of cell cycle; regulation of nucleocytoplasmic 
transport; response to interferon-alpha; type I interferon 
signaling pathway
H0Y3C5 HCK Tyrosine-protein kinase HCK 19 0 − 14.5 NA
B0QZ43 ERLIN1 Erlin-1 (Fragment) 19 0 − 14.5 ATP binding; peptidyl-tyrosine phosphorylation; protein tyrosine kinase activity
P02549 SPTA1
Spectrin alpha chain, 
erythrocytic 1 (Erythroid 
alpha-spectrin)
16 0 − 12.3
actin filament binding; actin filament capping; actin filament 
organization; axon guidance; calcium ion binding; cuticular 
plate; cytosol; hemopoiesis; intrinsic component of the 
cytoplasmic side of the plasma membrane; lymphocyte 
homeostasis; plasma membrane organization; porphyrin-
containing compound biosynthetic process; positive 
regulation of T cell proliferation; positive regulation 
of protein binding; regulation of cell shape; spectrin; 
spectrin-associated cytoskeleton; structural constituent of 
cytoskeleton
Q8IVF2 AHNAK2 Protein AHNAK2 15 0 − 11.6 nucleus
O60449 LY75 Lymphocyte antigen 75 (CD antigen CD205) 14 0 − 10.9
carbohydrate binding; endocytosis; immune response; 
inflammatory response; integral component of plasma 
membrane; receptor activity
Q9ULV0 MYO5B Unconventional myosin-Vb 14 0 − 10.9
ATP binding; cytoplasmic vesicle membrane; microfilament 
motor activity; myosin complex; protein complex; protein 
transport; transmembrane transport; vesicle-mediated 
transport; water transport
Table 1.  Top 10 proteins unique to CN ascites tumor cells. Rsc: Spectral count ratio (CR /CN), NA: Not 
available.
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Proteome data enrichment and pathway analysis. We subjected the proteome profiles of proteins 
from CN and CR population to analyses by KEGG, DAVID, and Gene Ontology (Fig. 3C). Several clusters of 
interacting proteins were significantly (p < 0.05) enriched in CR compared to CN tumor cells. Among these, 
pathways associated with energy metabolism such as glycine/serine/proline and arginine as well as DNA mis-
match repair mechanisms were enriched in CR compared to the CN population. In contrast, certain components 
of proteins involved with cell-cell adhesion and junction formation were significantly diminished in CR com-
pared to CN tumor cells.
Discussion
The successful clinical outcomes in terms of long-term recurrence free survival and > 5 year overall survival in 
ovarian cancer patients are rare. Hence, there is an urgent need for investigations into the traits of chemoresistant 
cells which are associated with recurrence with the aim of designing therapies which would specifically target the 
identified ‘chemoresistant traits’. We hypothesize that recurrence in ovarian cancer patients is largely dictated by 
the tumor cells that survive chemotherapy treatments, and a comparative study at the protein level of populations 
of cells isolated from the ascites of CN and CR ovarian cancer patients represents an important missing link to the 
recurrent disease. With this goal in mind, label-free quantitative proteome profiling was performed for the first 
time on a set of isolated tumor cells obtained from the ascites of advanced-stage CN and CR serous ovarian cancer 
patients in order to identify and understand the CR-associated proteins and pathways that could be involved in 
recurrence and subsequent progression of the disease.
Among the proteins identified, approximately 20% and 15% of the proteins were unique to CN and CR sam-
ples, respectively. Among the unique proteins, there was a distinct difference in the expression of host immune 
associated MHC class antigens which has not previously been reported. While MHC class II antigen (HLA-DRB1) 
expression was unique for the CR population, the CN population on the other hand, expressed MHC class I 
antigen (HLA-C). This distinct difference in the expression of MHC class I and II molecules in the CN and CR 
populations may suggest distinct mechanisms of tumor antigen processing by the host immune system before 
and after cancer treatment. While the MHC class I molecules initiate natural adaptive immunity and binds and 
presents peptide fragments to cytotoxic CD8+ T cells, the adaptive humoral and cell-mediated immune responses 
stimulated by MHC class II molecules is orchestrated by CD4+ T helper cells. This MHC-dependent shift in the 
Figure 3. Validation of differentially regulated proteins between CN and CR non-adherent cellular-derived 
patient samples. (A) Representative Western blots of cellular proteins derived from non-adherent spheroid 
ascites tumor populations from CN (4 individual patient replicates) and CR (4 individual patient replicates) 
samples. Proteins examined are TOP2A, PYCR2 and PPL. Total protein load was obtained by staining the 
membrane with Deep Purple. (B) Densitometry analysis was performed using ImageStudio v5, with mean pixel 
intensity normalized to background. Data is expressed as mean ± SEM of n = 4 samples/group performed in 
triplicate. Significance was determined using Student’s t-test with * p < 0.05 considered statistically significant 
(C) KEGG pathway enrichment analysis of proteins identified enriched in CR. Proteins identified enriched in 
CR vs CN (based on label-free spectral counting, Rsc > 2, Fisher’s exact test < 0.05) were functionally annotated 
to identify enriched biological pathways using the KEGG database. Only significantly enriched KEGG 
functional categories (p < 0.05) are depicted according to their protein number. The analysis yielded a strong 
significance for proteins associated with ‘energy metabolism’ and ‘DNA mismatch repair mechanisms’ pathways.
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adaptive immune response after chemotherapy treatment may occur paradoxically as a consequence of genotoxic 
stress following DNA damage response22. This would result in the change of a whole range of cytokine/chemok-
ine expression and signalling proteins/pathways and needs detailed further investigation. A recent global gene 
expression study on ovarian serous carcinomas representing low and high infiltration of cytotoxic T cells has 
identified cytotoxic T lymphocyte associated genes and pathways which showed strong immunohistochemical 
correlation with both MHC class I and II membrane expression, parts of the antigen processing and presentation 
pathways and cytotoxic T lymphocyte (CTL) recruitment23.
Consistent with the unique expression of MHC class I antigens in the CN population, we report unique expres-
sion of the IFNγ induced protein, Mx2, which previously has been associated with cytokine/chemokine associated 
immune responses in viral transfected cells24. We also report the unique expression of HCK, a member of the SRC 
family of cytoplasmic tyrosine kinases (SFKs) involved with immune cell migration/invasion and macrophage 
polarization to activated phenotype25 in CN samples. In addition, IDO1, a rate limiting enzyme which regulates 
the metabolism of essential amino acid tryptophan was unique to the CN population. IDO1 has previously been 
associated with the suppression of CD8+ and CD4+ T cells26 and has been shown to be involved with the perito-
neal dissemination of ovarian cancer through the inhibition of natural killer cell function27. IDO1 has also been 
identified as a marker for poor prognosis in serous ovarian cancer patients28. The expression of IDO1 by CN cells 
was consistent with the unique expression of kynureninase which acts on the accumulated tryptophan metabolite 
kynurenine and has been shown to be essential for stem cell biology and inflammation associated cancers29.
Contrary to the above findings, an autocrine cytokine/JAK/STAT signalling has been shown to induce kynure-
nine synthesis in multidrug resistant human cancer cells30. In this context, we have recently reported significantly 
enhanced activation of the JAK2/STAT3 pathway in response to chemotherapy treatment in ovarian cancer cells 
in vitro and in in vivo mouse xenograft models31,32. We have also reported enhanced activation of STAT3 in 
Protein 
Accession
Gene 
symbol Protein Description CN CR RSC Gene ontology (GO)
P23378 GLDC
Glycine dehydrogenase 
[decarboxylating], 
mitochondrial (EC 1.4.4.2)
0 21 19.9
electron carrier activity; glycine catabolic process; glycine 
dehydrogenase (decarboxylating) activity; lyase activity; 
mitochondrion; pyridoxal phosphate binding
P21266 GSTM3 Glutathione S-transferase Mu 3 (EC 2.5.1.18) 0 21 19.9
cellular detoxification of nitrogen compound; cytosol; 
establishment of blood-nerve barrier; glutathione 
binding; glutathione derivative biosynthetic process; 
glutathione metabolic process; glutathione transferase 
activity; nitrobenzene metabolic process; protein 
homodimerization activity; response to estrogen; 
xenobiotic catabolic process
Q56FN6 HLA-DRB1 MHC class II antigen 0 16 15.5
MHC class II protein complex; antigen processing and 
presentation of peptide or polysaccharide antigen via 
MHC class II; immune response; integral component of 
membrane
Q13085 ACACA Acetyl-CoA carboxylase 1 (EC 6.4.1.2) 0 13 12.8
ATP binding; acetyl-CoA carboxylase activity; 
acetyl-CoA metabolic process; biotin carboxylase 
activity; biotin metabolic process; carnitine shuttle; 
cytosol; energy reserve metabolic process; fatty acid 
biosynthetic process; lipid homeostasis; long-chain 
fatty-acyl-CoA biosynthetic process; malonyl-CoA 
biosynthetic process; metal ion binding; mitochondrion; 
multicellular organismal protein metabolic process; 
positive regulation of cellular metabolic process; protein 
homotetramerization; tissue homeostasis; triglyceride 
biosynthetic process
Q52NV4 HRS Histidyl-tRNA synthetase 0 12 11.9 ATP binding; cytoplasm; histidine-tRNA ligase activity; histidyl-tRNA aminoacylation
C9J837 RAB3GAP1 Rab3 GTPase-activating protein catalytic subunit 0 11 11.0
Rab GTPase activator activity; centrosome; cytoplasm; 
nucleus; positive regulation of Rab GTPase activity
P42771 CDKN2A Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3 0 9 9.2
G1/S transition of mitotic cell cycle; NF-kappaB binding; 
Ras protein signal transduction; cell cycle arrest; cell 
cycle checkpoint; cyclin-dependent protein serine/
threonine kinase inhibitor activity; cytosol; negative 
regulation of NF-kappaB transcription factor activity; 
negative regulation of cell growth; negative regulation 
of cell proliferation; negative regulation of cell-matrix 
adhesion; negative regulation of cyclin-dependent 
protein serine/threonine kinase activity; negative 
regulation of transcription, positive regulation of cellular 
senescence; positive regulation of macrophage apoptotic 
process; positive regulation of smooth muscle cell 
apoptotic process; replicative senescence; senescence-
associated heterochromatin focus; senescence-associated 
heterochromatin focus assembly
B4DF41 MSH6 DNA mismatch repair protein Msh6 0 9 9.2
ATP binding; mismatch repair; mismatched DNA 
binding
B3KMS0 NACAPD2 Condensin complex subunit 1 0 9 9.2 mitotic chromosome condensation; nucleus
D6RE83 UCHL1 Ubiquitin carboxyl-terminal hydrolase isozyme L1 0 8 8.3
cytoplasm; nucleus; ubiquitin thiolesterase activity; 
ubiquitin-dependent protein catabolic process
Table 2.  Top 10 proteins unique to CR ascites tumor cells. Rsc: Spectral count ratio (CR /CN).
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isolated ascites-derived CR tumor cells compared to CN tumor cells33 and enhanced gene expression of STAT3 in 
CR tumor cells compared to CN tumors34. This is consistent with the significantly enhanced expression of STAT3 
in CR tumors reported in this study.
Recent studies have led to an appreciation of the importance of metabolic reprogramming in cancer cells35. 
Cancer cells (including those from ovarian tumors) possess a fundamentally altered metabolism that enables 
tumorigenicity36. Besides studies on tumor-associated glycolysis, research into glycine37, proline38, asparagine39, 
tryptophan30, citrulline40, lipid41 and cholesterol metabolism are gaining momentum in cancer biology. 
Alterations in the metabolism of amino acids and lipids have been shown to contribute to drug-resistance in 
ovarian cancer cells36. The expression of GLDC which is unique to the CR population was shown to induce 
dramatic changes in glycolysis, glycine/serine and pyrimidine metabolism, regulate cancer cell proliferation and 
was shown to be essential for the sustenance of tumor initiating non-small cell lung cancer37. Even though the 
expression of this enzyme has not been previously demonstrated in ovarian cancer, aberrant up regulation of 
GLDC expression was significantly associated with the poor mortality in lung cancer and has been observed in 
multiple cancer types37. In addition, the expression of lipogenic enzyme ACC which previously has been shown to 
be highly expressed in some primary tumors41 was also unique to CR population. FDFT1 is another up regulated 
protein in the CR cohort which plays an important role in the cholesterol biosynthesis pathway42. Compared to 
non-cancerous tissues, prostate cancer specimens were shown to have enhanced expression of FDFT143 where it 
mediated the synthesis of the cholesterol content of membrane lipid rafts44. In addition, FDFT1 induced tumor 
necrosis factor receptor 1 enrichment in lipid rafts promoted lung cancer metastasis45. These findings underscore 
the importance of de novo cholesterol biosynthesis in ascites-derived CR tumor cells and suggest that FDFT1 may 
be a potential target for overcoming chemoresistance.
Besides cholesterol biosynthesis, elevated production of the glycosaminoglycan, hyaluronic acid has been 
strongly implicated in tumorigenesis and drug resistant ovarian cancer46. Hence, it is not surprising that UGDH, 
which is involved in the synthesis of hyaluronan precursor UDP-glucuronic acid, is elevated several-fold in CR 
Protein 
Accession
Gene 
symbol Protein Description CN CR RSC Gene ontology (GO)
Q99715 COL12A1 Collagen alpha-1 (XII) chain 1 23 12.1
cell adhesion; collagen catabolic process; collagen fibril organization; collagen type XII; 
endoplasmic reticulum lumen; extracellular matrix disassembly; extracellular matrix 
structural constituent conferring tensile strength; extracellular space; extracellular 
vesicular exosome; skeletal system development
P08243 ASNS Asparagine synthetase [glutamine-hydrolyzing] 1 20 10.6
ATP binding; L-asparagine biosynthetic process; activation of signaling protein activity 
involved in unfolded protein response; asparagine biosynthetic process; asparagine 
synthase (glutamine-hydrolyzing) activity; cellular protein metabolic process; cellular 
response to glucose starvation; cellular response to hormone stimulus; cofactor binding; 
cytosol; glutamine metabolic process; liver development; negative regulation of apoptotic 
process; positive regulation of mitotic cell cycle; response to amino acid; response to 
follicle-stimulating hormone; response to light stimulus; response to mechanical stimulus; 
response to methotrexate; response to toxic substance
P37268 FDFT1
Squalene synthase 
(Farnesyl-diphosphate 
farnesyltransferase)
1 12 6.6
cellular lipid metabolic process; cholesterol biosynthetic process; endoplasmic 
reticulum membrane; farnesyl diphosphate metabolic process; farnesyl-diphosphate 
farnesyltransferase activity; integral component of membrane; isoprenoid biosynthetic 
process; oxidoreductase activity; squalene synthase activity
O60701 UGDH UDP-glucose 6-dehydrogenase 3 23 6.4
NAD binding; UDP-glucose 6-dehydrogenase activity; UDP-glucose metabolic process; 
UDP-glucuronate biosynthetic process; cellular glucuronidation; cytosol; electron carrier 
activity; gastrulation with mouth forming second; glycosaminoglycan biosynthetic process; 
xenobiotic metabolic process
Q96C36 PYCR2 Pyrroline-5-carboxylate reductase 2 4 26 5.8 L-proline biosynthetic process; cytoplasm; pyrroline-5-carboxylate reductase activity
Q9UKF6 CPSF3
Cleavage and 
polyadenylation specificity 
factor subunit 3
1 10 5.6
5′ -3′ exonuclease activity; RNA binding; endoribonuclease activity; histone mRNA 
3’-end processing; mRNA cleavage; mRNA cleavage and polyadenylation specificity 
factor complex; mRNA export from nucleus; mRNA polyadenylation; mRNA splicing, 
via spliceosome; metal ion binding; ribonucleoprotein complex; termination of RNA 
polymerase II transcription
B4DHQ3 PSAT Phosphoserine aminotransferase 1 10 5.6
L-serine biosynthetic process; O-phospho-L-serine:2-oxoglutarate aminotransferase 
activity; pyridoxal phosphate binding
Q8NFF5 FLAD1 FAD synthase 3 19 5.3
ATP binding; FAD biosynthetic process; FMN adenylyltransferase activity; Mo-
molybdopterin cofactor biosynthetic process; cytosol; mitochondrial matrix; riboflavin 
metabolic process
O15230 LAMA5 Laminin subunit alpha-5 1 9 5.1
angiogenesis; cell migration; cell proliferation; cell recognition; cilium assembly; 
cytoskeleton organization; embryo development; endothelial cell differentiation; 
establishment of protein localization to plasma membrane; extracellular matrix 
organization; extracellular space; focal adhesion assembly; integrin binding; integrin-
mediated signaling pathway; laminin-1 complex; laminin-10 complex; laminin-11 
complex; laminin-5 complex; lung development; morphogenesis of a polarized epithelium; 
morphogenesis of embryonic epithelium; muscle organ development; neural crest 
cell migration; odontogenesis of dentin-containing tooth; regulation of cell adhesion; 
regulation of cell migration; regulation of cell proliferation; regulation of embryonic 
development; structural molecule activity; substrate adhesion-dependent cell spreading
Q6UX53 METTL7B Methyltransferase-like protein 7B 1 9 5.1 methyltransferase activity
Table 3.  Top 10 enriched proteins identified in CR compared to CN ascites tumor cells. Rsc: Spectral count 
ratio (CR/CN).
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tumor cells. In addition, we report a significantly increased expression of PYCR2, a cytosolic enzyme crucial for the 
metabolism of proline under conditions of nutrient stress38. Metabolism of proline which is found abundantly in 
collagens associated with the connective tissues is an energy source which provides carbon for tricarboxylic cycle 
and also participates in proline cycle38. In addition, ASNS, up regulated in CR, catalyses the conversion of aspartate 
and glutamine to asparagine and glutamate in an ATP-dependent manner. ASNS shown to be up regulated in several 
solid tumors and acute lymphoblastic leukaemia is a stress-regulated enzyme enhanced as a result of tumor adapta-
tion to nutrient deprivation and/or hypoxia47. ASNS has recently been identified as a new predictive biomarker for 
ovarian cancer treatment which can be used for L-Asparaginase therapy in a low-ASNS subset of ovarian cancer40.
We also report the expression of GST-M3 unique to CR population. GSTs comprise a family of Phase II drug 
metabolising enzymes which catalyse the conjugation of reduced glutathione to reactive electrophile as part of 
cellular adaptive response to chemicals and oxidative stress48. Hence, the unique expression of GST-M3 in CR 
ascites-derived cells may imitate the chemoresistant phenotype, which is also consistent with the unique expres-
sion of MSH6, mutations of which have been reported in hereditary ovarian cancer49. Even though the expression 
of UCHL1 and CDKN2A were observed in CR population it is not clear if these proteins were epigenetically silent 
as both these proteins have been shown to act as putative tumor suppressors in ovarian cancer cells50,51.
In addition, CR tumors were also enriched in ABCC4 proteins52 and TOP2α , which is associated with drug 
resistance  [Rsc = 3.7]53. Other proteins of interest were Protein DJ-1, shown to be crucial for the peritoneal 
metastasis of gastric cancer54, Agrin, a proteoglycan, which has been shown to play an oncogenic role in hepa-
tocellular carcinoma55 and previously identified in ascites of ovarian cancer patients56, and the inflammatory 
cytokine MIF, shown to contribute to immune escape of ovarian cancer patients by down regulating NK cell 
receptor NKG2D57. Enhanced expression of MIF has previously been reported in the serum of ovarian cancer 
patients and correlated with poor patient prognosis58. In addition, enhanced expression of haptoglobin, transfer-
rin and Chitinase-3-like protein 1 (CHI3L1) in CR ascites tumor cells have been reported previously in malignant 
ascites59.
Protein 
Accession
Gene 
symbol Protein Description CN CR RSC Gene ontology (GO)
B7Z416 DHRS9 Dehydrogenase/reductase SDR family member 9 48 46 − 13.0 oxidation-reduction process; oxidoreductase activity
Q16647 PTGIS Prostacyclin synthase 43 40 − 8.7
apoptotic signaling pathway; cellular response to hypoxia; cellular response 
to interleukin-1; cellular response to interleukin-6; cyclooxygenase pathway; 
endoplasmic reticulum membrane; extracellular space; heme binding; integral 
component of membrane; iron ion binding; monooxygenase activity; negative 
regulation of NF-kappaB transcription factor activity; negative regulation of 
inflammatory response; negative regulation of nitric oxide biosynthetic process; 
nucleus; oxidoreductase activity, acting on paired donors, with incorporation 
or reduction of molecular oxygen; positive regulation of angiogenesis; positive 
regulation of execution phase of apoptosis; positive regulation of peroxisome 
proliferator activated receptor signaling pathway; prostaglandin-I synthase activity; 
xenobiotic metabolic process
B4DKB2 ECE1 Endothelin-converting enzyme 1 42 38 − 6.7 metalloendopeptidase activity; proteolysis
K7EKI8 PPL Periplakin 211 187 − 6.4 cytoskeleton
P26583 HMGB2 High mobility group protein B2 14 13 − 5.7
DNA binding, bending; DNA topological change; RAGE receptor binding; apoptotic 
DNA fragmentation; base-excision repair, DNA ligation; cell chemotaxis; cellular 
response to lipopolysaccharide; chemoattractant activity; damaged DNA binding; 
double-stranded DNA binding; extracellular space; male gonad development; 
negative regulation of extrinsic apoptotic signaling pathway via death domain 
receptors; negative regulation of transcription, DNA-templated; nucleosome 
assembly; phosphatidylinositol-mediated signaling; positive regulation of DNA 
binding; positive regulation of endothelial cell proliferation; positive regulation of 
erythrocyte differentiation; positive regulation of megakaryocyte differentiation; 
positive regulation of nuclease activity; positive regulation of transcription from RNA 
polymerase II promoter; protein complex; response to steroid hormone; sequence-
specific DNA binding transcription factor activity; single-stranded DNA binding; 
transcription regulatory region DNA binding
P09913 IFIT2
Interferon-induced protein 
with tetratricopeptide 
repeats 2
14 13 − 5.7
RNA binding; apoptotic mitochondrial changes; cellular response to interferon-
alpha; cytosol; defense response to virus; endoplasmic reticulum; negative regulation 
of protein binding; positive regulation of apoptotic process; response to virus; type I 
interferon signaling pathway
Q13753 LAMC2 Laminin subunit gamma-2 34 30 − 5.3
cell adhesion; cell cortex; epidermis development; extracellular matrix organization; 
extracellular region; extracellular space; hemidesmosome assembly; heparin binding; 
laminin-2 complex; laminin-5 complex; membrane; perinuclear region of cytoplasm
A8K8G0 HDGF Hepatoma-derived growth factor 33 29 − 5.1 NA
P43155 CRAT Carnitine O-acetyltransferase 12 11 − 4.9
carnitine O-acetyltransferase activity; carnitine metabolic process, CoA-linked; 
endoplasmic reticulum; fatty acid beta-oxidation using acyl-CoA oxidase; 
mitochondrial inner membrane; mitochondrion; peroxisomal matrix; transport
P08582 MFI2
Melanotransferrin 
(Melanoma-associated 
antigen p97) ( CD228)
12 11 − 4.9
anchored component of membrane; cellular iron ion homeostasis; extracellular 
region; ferric iron binding; integral component of plasma membrane; iron ion 
binding; iron ion transport
Table 4.  Top 10 diminished proteins identified in CR compared to CN ascites tumor cells. Rsc: Spectral 
count ratio (CR /CN), NA: Not available.
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Other proteins of specific interest down regulated in CR tumor cells were members of plakin family such as 
PPL, EVPL and Plectin which function as ‘molecular bridges’ linking the intracellular cytoskeleton and cell-cell 
junctions60. PPL, EVPL and Plectin interact with each other and participate in the assembly of intermediate fila-
ment organisation (such as keratins and vimentins) in epithelial cells60,61. Loss of PPL expression has been docu-
mented in urethelial and esophageal carcinomas62 and aberrant DNA hypermethylation of PPL and interacting 
EVPL have been reported to be responsible for this down regulation in squamous cell carcinomas63. PPL knock-
down has been associated with reduced cellular movement and ECM adhesion in malignant pharyngeal cells64. 
On the other hand, significantly increased expression of Plectin compared to non-cancerous tissues has been 
reported in invasive head and neck squamous cell carcinomas and that has been correlated with poor prognosis 
of the patients65. This is consistent with the role of Plectin in association with vimentin in providing a scaffold 
for invadopodia, facilitating cancer cell invasion and metastasis66. In addition, in pancreatic cancer unexpected 
extracellular surface expression of Plectin has recently been reported and this was shown to be necessary for 
exosome production in conjunction with proteins Rab27a and − b and required for sustaining tumor growth in 
immunocompetent mouse models67. Our study also identified significantly high expression of Rab27a and –b in 
CN samples compared to CR samples (Rsc = − 3.5 and − 4.1 respectively).
In summary, we demonstrate for the first time a novel pattern of protein expression in cells isolated from 
CR tumors compared to CN tumors obtained from the ascites of ovarian cancer patients. This preliminary 
profiling-based study utilised a systematic approach of studying only the ascites-derived tumor cells before and after 
chemotherapy treatments without any background influence from other interacting cells in the tumor microenvi-
ronment. An underlying dependence of CR tumor cells for energy metabolism pathways such as enhanced expres-
sion of GLDC, ACC, ASNS, FDFT1, UGDH, PYCR2, etc was noted. This may suggest a shift of glucose-dependent 
mitochondrial function for energy generation for the biosynthesis of secondary metabolites such as glycine/serine, 
fatty acid, aspartate, cholesterol, hyaluronic acid, proline, which may be involved with the survival of anchorage 
independent free-floating, genotoxic-stressed, chemoresistant tumor cells. In that setting, concomitant enrich-
ment of proteins involved with DNA repair (MSH6, TOP2A, CDKN2A, AURKA, AURKB) and a member of 
the ATP-binding cassette transporters (ABCC4) is consistent with the chemoresistant phenotype of CR tumors. 
Moreover, novel expression of oncogenic Protein DJ-1 previously implicated with the peritoneal dissemination 
of gastric cancer, makes these findings worthy of future investigation into the role of these proteins in CR biology. 
Importantly, this study identified a distinct host immune surveillance processes operated by two distinct adaptive 
immune responses MCH-Class 1 and Class 11 molecules in CN and CR patients respectively. In addition, down 
regulation of proteins associated with hemidesmosomes and cell cytoskeletal adhesion, such as proteins of the 
plakin family such as PPL, EVPL, Epiplakin, Plectin etc defines the true free-floating characteristics of CR tumors in 
the ascites microenvironment. This preliminary study builds the framework for future studies, which should focus 
on particular proteins and pathways of interest that may have therapeutic potential in reducing ascites-associated 
chemoresistance and recurrences in ovarian cancer patients. Differential distribution of proteins in the isolated CR 
compared to CN tumor cells obtained from the ascites of ovarian cancer patients are depicted in Fig. 4.
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